Logo

Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

Share this
Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

Lantheus' Pylarify (piflufolastat F 18) Injection Receives the US FDA's Approval for the Treatment of Prostate Cancer

Shots:

  • The approval is based on data from 2 pivotal studies i.e OSPREY & CONDOR evaluating the safety & diagnostic performance of Pylarify in patients with prostate cancer
  • Results: 1st study showed improvement in specificity & PPV compared with conventional imaging for metastatic prostate cancer & 2nd study showed high CLRs & detection rates includes low PSA values (median PSA is 0.8 ng/mL) for biochemically recurrent prostate cancer & non-informative baseline imaging
  • Pylarify is the 1st commercially available approved PSMA PET imaging agent for prostate cancer & will be available immediately in mid-Atlantic & southern regions- expected to be broadly available in the US at the end of 2021

  | Ref: Business Wire | Image: PR Newswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions